Novo Nordisk decided to discontinue its long-acting insulin Levemir last November, and three Democrats in the Senate want to know why, laying out their questions in a letter to leaders of the company on Tuesday.
Sens. Jeanne Shaheen (D-NH), Elizabeth Warren (D-MA) and Raphael Warnock (D-GA) sought more information on supply constraints and whether Novo would consider producing Levemir until biosimilars are available. They gave Novo until May 1 to respond to the questions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.